Quest Partners LLC Grows Stock Holdings in Zynex, Inc. (NASDAQ:ZYXI)

Quest Partners LLC grew its holdings in Zynex, Inc. (NASDAQ:ZYXI) by 646.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,926 shares of the company’s stock after acquiring an additional 11,195 shares during the period. Quest Partners LLC’s holdings in Zynex were worth $120,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. BNP Paribas Financial Markets raised its position in Zynex by 41.2% in the fourth quarter. BNP Paribas Financial Markets now owns 34,249 shares of the company’s stock valued at $373,000 after purchasing an additional 9,997 shares during the period. Trexquant Investment LP lifted its position in Zynex by 46.4% during the 4th quarter. Trexquant Investment LP now owns 122,671 shares of the company’s stock worth $1,336,000 after acquiring an additional 38,865 shares in the last quarter. Cim LLC acquired a new position in Zynex during the 4th quarter worth approximately $446,000. Congress Asset Management Co. MA boosted its holdings in Zynex by 1.0% in the 1st quarter. Congress Asset Management Co. MA now owns 118,376 shares of the company’s stock worth $1,464,000 after acquiring an additional 1,225 shares during the period. Finally, Bridge City Capital LLC grew its position in Zynex by 4.1% in the first quarter. Bridge City Capital LLC now owns 186,665 shares of the company’s stock valued at $2,309,000 after acquiring an additional 7,270 shares in the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

Zynex Stock Performance

Shares of ZYXI opened at $7.97 on Tuesday. The firm has a market cap of $253.25 million, a price-to-earnings ratio of 34.65 and a beta of 0.54. The company has a quick ratio of 3.22, a current ratio of 4.06 and a debt-to-equity ratio of 1.79. The business’s 50 day moving average is $8.43 and its two-hundred day moving average is $10.07. Zynex, Inc. has a 52-week low of $7.04 and a 52-week high of $13.77.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $49.88 million during the quarter, compared to analyst estimates of $51.99 million. Zynex had a net margin of 3.12% and a return on equity of 14.15%. The company’s revenue was up 11.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 earnings per share. Analysts forecast that Zynex, Inc. will post 0.22 EPS for the current fiscal year.

Insider Buying and Selling

In other Zynex news, COO Anna Lucsok sold 8,083 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total transaction of $64,906.49. Following the sale, the chief operating officer now owns 16,980 shares in the company, valued at $136,349.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Zynex news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the transaction, the chief operating officer now owns 16,980 shares of the company’s stock, valued at $136,349.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Joshua R. Disbrow bought 7,000 shares of the stock in a transaction on Monday, July 29th. The shares were acquired at an average price of $8.32 per share, with a total value of $58,240.00. Following the purchase, the director now owns 72,000 shares of the company’s stock, valued at $599,040. The disclosure for this purchase can be found here. Insiders own 52.13% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on ZYXI shares. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Zynex in a research report on Wednesday, September 4th. Royal Bank of Canada cut their price objective on shares of Zynex from $15.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, July 26th.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.